NCT04711902 - Study of Efficacy and Safety of Secukinumab in Chinese Subjects With Active PsA Compared to Placebo. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 24, 2021

Primary Completion Date

June 2, 2022

Study Completion Date

March 10, 2023

Conditions

Psoriatic Arthritis

Interventions

DRUG

AIN457

Secukinumab 150 mg was supplied in 1.0 mL prefilled syringe, administered via subcutaneous injection

OTHER

Secukinumab Placebo

Secukinumab placebo was supplied in 1.0 mL prefilled syringe, administered via subcutaneous injection

Trial Locations (12)

Novartis Investigative Site, Hohhot

Novartis Investigative Site, Beijing

Novartis Investigative Site, Shanghai

Novartis Investigative Site, Nanjing

Novartis Investigative Site, Jinan

Novartis Investigative Site, Nanchang

Novartis Investigative Site, Pingxiang

Novartis Investigative Site, Chongqing

Novartis Investigative Site, Zhuzhou

Novartis Investigative Site, Guangzhou

Novartis Investigative Site, Chengdu

Novartis Investigative Site, Baotou